Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29663590 | 0.87 | SMN1; SMN2 (0.66) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2EPHX2 | |
| SCHEMBL23120213 | 0.87 | SMN1; SMN2 (0.66) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2EPHX2 | |
| SCHEMBL10886971 | 0.84 | POLB (0.51) | ALDH1A1POLBCYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL24499540 | 0.84 | SMN1; SMN2 (0.51) | ALDH1A1POLBCYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL24498947 | 0.83 | ALDH1A1 (0.65) | ALDH1A1POLBSMN1; SMN2KMT2APKM | |
| SCHEMBL24499181 | 0.83 | SMN1; SMN2 (0.53) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2RAB9A | |
| SCHEMBL8533501 | 0.82 | POLB (0.76) | ALDH1A1POLBRAB9AKMT2ANPSR1 | |
| SCHEMBL29688982 | 0.82 | POLB (0.76) | ALDH1A1POLBRAB9AKMT2ANPSR1 | |
| SCHEMBL14602134 | 0.81 | CYP1A2 (0.51) | ALDH1A1POLBCYP1A2CYP2C19SMN1; SMN2 | |
| SCHEMBL27937420 | 0.81 | ALDH1A1 (0.63) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109338-B2 | For use in the prophylaxis and the treatment of Picornavirus and human rotavirus infections. | MARUISHI PHARMACEUTICAL CO., LTD. (JP) | 2006-09-19 | — | — | US | disclosed |
| US-20040009977-A1 | 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds | MARUISHI PHARMACEUTICAL CO., LTD. (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-1380575-A1 | 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds | Maruishi Pharmaceutical Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
| US-6541470-B1 | Have a potent antiviral activity against picornaviruses and rotaviruses. | MARUISHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-01 | — | — | US | disclosed |
| EP-1081138-A1 | 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds | Maruishi Pharmaceutical Co., Ltd. (JP) | 2001-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009977-A1 | 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds | MAVS, IRF3, EIF2AK2 | ALDH1A1 1671/4885POLB 194/4885CYP1A2 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.